Overview
To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS)
Description
In order to confirm the promising results of the 36 Gy dose level in the DOREMY trial (NCT02106312) and to compare outcome with other local treatment approaches.
Eligibility
Inclusion Criteria:
- Age > 18 years
- Biopsy proven MLS, including the reciprocal chromosomal translocation t(12;16)(q13;p11)
- ECOG PS 0-2
- Written informed consent to share coded information in this international Registry
Exclusion Criteria:
- Prior radiotherapy to the target area
- Pregnancy